BVF Inc. IL Sells 717,000 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

BVF Inc. IL decreased its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 15.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 3,944,194 shares of the company's stock after selling 717,000 shares during the period. Tyra Biosciences accounts for about 1.9% of BVF Inc. IL's holdings, making the stock its 12th largest position. BVF Inc. IL owned about 7.79% of Tyra Biosciences worth $54,824,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in TYRA. Rhumbline Advisers grew its holdings in Tyra Biosciences by 4.1% during the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock valued at $364,000 after purchasing an additional 1,027 shares during the last quarter. RA Capital Management L.P. grew its stake in Tyra Biosciences by 2.1% in the 4th quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company's stock valued at $147,858,000 after buying an additional 220,681 shares during the last quarter. Barclays PLC lifted its position in Tyra Biosciences by 200.5% during the 3rd quarter. Barclays PLC now owns 37,625 shares of the company's stock worth $884,000 after acquiring an additional 25,106 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Tyra Biosciences by 1.1% during the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company's stock valued at $8,667,000 after acquiring an additional 3,896 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $761,000. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Stock Performance

Shares of TYRA stock traded down $0.87 during mid-day trading on Wednesday, reaching $9.13. The company's stock had a trading volume of 582,218 shares, compared to its average volume of 257,360. The firm's 50-day moving average is $9.68 and its two-hundred day moving average is $13.56. The company has a market cap of $484.71 million, a P/E ratio of -5.67 and a beta of 1.17. Tyra Biosciences, Inc. has a 1-year low of $6.42 and a 1-year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. Sell-side analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Wedbush restated an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, March 31st. Finally, UBS Group began coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They issued a "buy" rating and a $28.00 target price for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat, Tyra Biosciences has an average rating of "Buy" and an average target price of $30.83.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.